drugset / Trial / NCT00445146
Safety of EVG+RTV Administered With Other Antiretroviral Agents for the Treatment of HIV-1 Infection
NaSingle-groupOpen-labelTreatment
Summary
The main objective of this study is to observe the long-term safety of elvitegravir (EVG) boosted with ritonavir (RTV) in combination with other antiretroviral (ARV) agents in participants who have completed a prior EVG+RTV treatment study.
Timeline
- Start
- 2007-02
- Primary completion
- 2015-03
- Completion
- 2015-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | elvitegravir | Small molecule | 85 mg | Oral |
| Subject | elvitegravir | Small molecule | 150 mg | Oral |
| Subject | elvitegravir | Small molecule | 300 mg | Oral |
| Background | Ritonavir | Other / unclassified | 100 mg | Oral |